Polymorphic Sodium Salt for Heterotopic Ossification Prevention

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for heterotopic ossification, a severe pathological condition characterized by uncontrolled bone formation in non-skeletal tissues, lack effective preventive measures beyond surgical removal and radiation, with no pharmaceutical interventions available.

Innovation Solution

The compound (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl)benzoic acid or its pharmaceutically acceptable salts, particularly the sodium salt, are used to prevent the proliferation of osteoblasts that cause heterotopic ossification, with a dose range of 1 to 30 mg/kg, preferably 10 mg/kg, demonstrating efficacy in various disease models.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If surgical removal and radiation are used to treat heterotopic ossification, then existing bone formation can be removed, but preventive measures are lacking and the condition may recur

Engineering Contradiction:

Improveprevention effectivenessVSAvoidavailability of pharmaceutical interventions

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The compound (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl)benzoic acid is administered before heterotopic ossification fully develops to prevent osteoblast proliferation and bone formation, rather than treating after surgical removal is needed

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent replaces mechanical surgical removal and radiation therapy with a pharmaceutical compound that chemically inhibits osteoblast proliferation and heterotopic bone formation through EP4 receptor antagonism

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Object-affected harmful factors

If anti-inflammatory drugs and COX2 inhibitors are used to treat heterotopic ossification, then inflammation may be reduced, but they are ineffective in controlling bone formation

Engineering Contradiction:

Improveinflammation controlVSAvoidbone formation control

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The compound specifically targets osteoblast proliferation and heterotopic bone formation pathways through EP4 receptor antagonism, providing localized action on bone-forming cells rather than general anti-inflammatory effects

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent changes the therapeutic parameter from general anti-inflammatory action to specific inhibition of osteoblast proliferation and bone formation by targeting the EP4 receptor pathway, achieving superior efficacy in preventing heterotopic ossification

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS12433875B2(R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or its salt also in polymorphic form a for use in the prevention of heterotopic ossification

Publication Date: 2025.10.07 ROTTAPHARM BIOTECH SRL

AI summary

There is described a compound of formula (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl)benzoic acid or a pharmaceutically acceptable salt thereof or the form A of its sodium salt for use in the prevention of heterotopic ossification. Preferably such a compound is effective in a specific dose range.